With an estimated $21.5 billion in federal research and development (R&D) funding signed into law on February 17th, many suppliers are breathing a sigh of relief that the life science market will be immune from the global economic crisis. But it is unclear how quickly these funds will be released, what programs will be funded, […]
The life science industry is not immune from the global financial crisis. Pharmaceutical, biotechnology, academic and government labs are bracing for budget freezes and staff reductions. During this tumultuous time in our industry, the opportunity for life science suppliers to thrive-rather than survive-will be predicated on a detailed understanding of how labs will allocate 2009 […]
